Clayton Financial Group LLC Takes $1.43 Million Position in AbbVie Inc. $ABBV

Clayton Financial Group LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,172 shares of the company’s stock, valued at approximately $1,429,000. AbbVie accounts for about 1.0% of Clayton Financial Group LLC’s holdings, making the stock its 15th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Secured Retirement Advisors LLC raised its holdings in AbbVie by 43.0% in the 3rd quarter. Secured Retirement Advisors LLC now owns 1,623 shares of the company’s stock valued at $376,000 after acquiring an additional 488 shares during the last quarter. Financial Council LLC boosted its holdings in shares of AbbVie by 2.1% during the third quarter. Financial Council LLC now owns 6,008 shares of the company’s stock worth $1,391,000 after purchasing an additional 124 shares during the last quarter. Whitener Capital Management Inc. grew its position in shares of AbbVie by 3.7% in the third quarter. Whitener Capital Management Inc. now owns 40,298 shares of the company’s stock valued at $9,331,000 after purchasing an additional 1,427 shares during the period. Weinberger Asset Management Inc acquired a new position in AbbVie in the third quarter valued at $233,000. Finally, Gemmer Asset Management LLC lifted its position in AbbVie by 2.5% during the third quarter. Gemmer Asset Management LLC now owns 2,713 shares of the company’s stock worth $628,000 after buying an additional 65 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ABBV. UBS Group lifted their price target on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Evercore ISI upped their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Stock Up 0.6%

Shares of AbbVie stock opened at $230.18 on Friday. The company has a fifty day moving average price of $226.72 and a 200 day moving average price of $212.12. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market cap of $406.81 billion, a price-to-earnings ratio of 174.38, a price-to-earnings-growth ratio of 1.31 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.